[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100064674":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":24,"locations":24,"responsibleParty":32,"collaborators":24,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":24,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":24,"enrollmentInfo":43,"targetDuration":24,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":24,"overallStatus":52,"whyStopped":24,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":24},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL","Higher Potency Dose",[13],"Biological: Comparator: Varicella Zoster Virus Vaccine",{"label":15,"type":10,"description":16,"interventionNames":17},"2","Lower Potency Dose",[13],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Comparator: Varicella Zoster Virus Vaccine","Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (\\~207,000 plaque-forming units \\[PFU\\]\u002F0.65-mL dose)",[9],null,{"type":20,"name":21,"description":26,"armGroupLabels":27,"otherNames":24},"Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (\\~58,000 plaque-forming units \\[PFU\\]\u002F0.65-mL dose)",[15],[29],{"name":30,"affiliation":5,"role":31},"Medical Monitor","STUDY_DIRECTOR",{"type":33,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100064674","phase-3-evaluation-of-the-safety-and-tolerability-of-a-higher-potency-dose-of-an-investigational-vaccine-among-adults-50-years-of-age-and-older-v211-009-100064674",true,"NCT00092417","Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)","Evaluation of the Safety and Tolerability of a Higher Potency Dose of Varicella Zoster Virus Vaccine Live (Oka\u002FMerck)Among Adults 50 Years of Age or Older","Inclusion Criteria:\n\n* Healthy individuals 50 years of age or older with a history of chickenpox who have not had herpes zoster\n\nExclusion Criteria :\n\n* Preexisting conditions that might affect vaccine safety such as conditions that inhibit an immune response","ALL","50 Years",{"count":44,"type":45},695,"ACTUAL","INTERVENTIONAL",[48],"PHASE3","This study compared the safety and tolerability profile of a higher potency investigational vaccine to that of the investigational vaccine at a lower potency dose.",[51],"Healthy","COMPLETED","2015-10-06",{"date":55,"type":56},"2015-10-07","ESTIMATED",{"date":58,"type":24},"2003-10",{"date":60,"type":45},"2004-06",{"name":5,"class":6}]